Ocrelizumab accepted for EMA review
Ocrelizumab accepted for EMA review
Roche has announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorisation Application (MAA) of ocrelizumab for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) in the European Union (EU)...Read more - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 11886 Views
-
Last post by NHE
-
- 0 Replies
- 1168 Views
-
Last post by NHE
-
- 0 Replies
- 1939 Views
-
Last post by frodo
-
- 0 Replies
- 1245 Views
-
Last post by frodo
-
- 0 Replies
- 2104 Views
-
Last post by NHE
-
- 0 Replies
- 1697 Views
-
Last post by frodo
-
- 0 Replies
- 1310 Views
-
Last post by NHE
-
- 1 Replies
- 1790 Views
-
Last post by frodo
-
- 0 Replies
- 2513 Views
-
Last post by NHE